CEO Andy Crockett (KalVista)
February 9, 2021 07:02 AM ESTUpdated 08:35 AM
R&D

KalVista sees a win in PhII for the rare ge­net­ic dis­or­der HAE as it con­tin­ues to chart a post-Mer­ck course

Max Gelman

Senior Editor

Rough­ly a year af­ter Mer­ck walked away from a part­ner­ship with KalVista fol­low­ing a flop in di­a­bet­ic mac­u­lar ede­ma, the biotech is back with da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times